CROI 2024: Opening lecture calls for scientists to speak up for LGBTQ+ rights in Uganda

IAS 2023: Bictegravir use in pregnancy: more data needed

IAS 2023: In-utero tenofovir-based PrEP has no effect on children’s bone mineral density

No vertical HIV transmissions in the UK from women eligible for supported breastfeeding

Adverse birth outcomes with diabetes and hypertensive disorders in pregnancy

Implications of restrictions on reproductive rights for HIV care in the USA and beyond

CROI 2023: Point-of-care testing for mothers and infants: results from the LIFE study

Zero transmission in France for mothers on ART from conception with undetectable viral load at delivery

Glasgow 2022: Vertical transmission rate below 0.3% among women living with HIV in the UK

Dolutegravir no longer linked to higher risk of neural tube defects: latest update from the Tsepamo study

Using PrEP during pregnancy is safe for children

CROI 2022: Higher maternal mortality and adverse birth outcomes among women with COVID-19 in Botswana

Few vertical HIV transmissions in the UK but contributing factors remain associated with inequality

No differences in outcomes among women with and without HIV with high-risk pregnancies and COVID-19

Dolutegravir-based regimens safe and effective in pregnancy and postpartum

CROI 2021: Pregnancy outcomes and weight gain with dolutegravir and TAF

Promising data for multipurpose technologies to prevent HIV and pregnancy

Adverse pregnancy outcomes among Spanish women hospitalised with COVID-19

No increase in adverse birth outcomes with IPT-exposure in pregnancy in two African cohorts

Neural tube defects in two of 1000 conception exposures with dolutegravir: reassuring update from Tsepamo study

Obesity linked to dolutegravir, especially with TAF, could increase risk of adverse pregnancy outcomes

Pregnancy meta-analysis: dolutegravir- versus efavirenz-based ART

Dolutegravir-based ART is safe and effective for pregnant women: first results from the VESTED trial

Postpartum weight gain is higher with dolutegravir- compared with efavirenz-based ART among African women

Antiretroviral pregnancy registry: dolutegravir update

Bictegravir/emtricitabine/tenofovir alafenamide appears to be safe and effective in women: results from a pooled analysis

No link between raltegravir and adverse birth outcomes in analysis in 2550 women

Low rates of pregnancy with three methods of contraception in the ECHO trial

Other pregnancy studies IAS 2019

Dolutegravir neural tube defect risk declines but still slightly higher than with other antiretrovirals

High rates of viral suppression with low dose efavirenz in pregnant Zambian women

Infant dolutegravir exposure through placental and breastmilk transfer  

Antiretroviral pharmacokinetics in pregnancy: update from IMPAACT P1026s

No increased adverse outcomes among women starting dolutegravir before conception in the ADVANCE study

Integrase inhibitors and neural tube defects: more data still needed

Dear Doctor letter: Increased risk of treatment failure and increased risk of mother-to-child transmission of HIV infection dues to lower exposure of elvitegravir and cobicistat during the second and third trimesters of pregnancy

Dolutegravir suppresses viral load faster than efavirenz in late pregnancy: results from DolPHIN-2

Raltegravir achieves swifter viral load suppression in pregnancy than efavirenz

Hepatitis C is an independent risk factor for preterm delivery in HIV positive women: data from a Warsaw cohort

Vertical transmission remains very low in UK and Ireland: update from the National Study of HIV in Pregnancy and Childhood 

No additional neural tube defects with preconception dolutegravir: data from three birth outcome cohorts

Insufficient data on risk of neural tube defects with exposure to elvitegravir or bictegravir exposure during preconception or first trimester

TAF exposures during pregnancy and postpartum appear adequate but more data are needed

High rate of unintended pregnancy among HIV positive African women on ART

WHO recommends dolutegravir widely but women’s access will depend on contraception provision (2018)

No additional neural tube defects among a further 170 preconception dolutegravir exposures in Botswana: Tsepamo study (July 2018)

Swifter viral load suppression with dolutegravir vs efavirenz in late pregnancy: results from DolPHIN-1

Preconception safety signal with dolutegravir: data from the Tsepamo study

Dolutegravir preconception signal: time is up for shoddy surveillance

Dolutegravir: need to consider all pros and cons before switching in pregnancy

Why U=U does not apply to breastfeeding

Janssen Dear Doctor letter: Prezista (darunavir), Rezolsta ▼(darunavir/cobicistat)and Symtuza ▼(darunavir/cobicistat/emtricitabine/tenofovir alafenamide)

Unbound dolutegravir plasma concentrations unchanged in pregnancy and standard dosing crosses the placenta in placental perfusion model

Reduced exposure to elvitegravir in pregnancy: results from the PANNA Network  

BHIVA statement on potential safety signal in infants born to women conceiving on dolutegravir

ViiV Dear Doctor letter: Neural tube defects reported in infants born to women exposed to dolutegravir at the time of conception

Potential safety signal for dolutegravir from the time of conception

Dolutegravir in pregnancy: early data reassuring but ongoing surveillance is still essential

Almost 1 in 8 people with symptoms turned away from sexual health clinics in SE London: 40% are under 25 and 6% under 18 years old

Key changes to upcoming UK HIV pregnancy guidelines (2018)

Pregnancy studies at 4th Joint BHIVA/BASHH Conference

Isoniazid preventive TB therapy in pregnancy and postpartum: recommendations now need to be re-evaluated

Efavirenz might decrease effectiveness of the vaginal contraceptive ring

Standard dose of dolutegravir sufficient in late pregnancy: interim results from DolPHIN-1 study

Standard once-daily dolutegravir dosing achieves target levels during pregnancy

Post navigation